GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2013

Altered Receptor Allows Tumors to Sneak by Immune System

  • The ability of tumors to evade being recognized by the immune system plays a critical role in cancer progression. Now, as discussed in the current issue of the Journal of Clinical Investigation, Gerard Blobe, M.D., Ph.D., and a team at Duke University have explored the tumor microenvironment and identified a mechanism by which tumors evade detection.

    Using mouse models of breast cancer and melanoma, they show that loss of the Type III TGF-β receptor (TGFBR3) in tumors promotes cancer progression by altering signaling in tumor-associated immune cells. The scientists say their study also supports the use of TGF-β inhibitors to enhance the efficacy of therapies that promote immune-mediated elimination of tumor cells.

    According to the researchers, TGFBR3 and its shed extracellular domain (sTGFBR3) regulate signaling pathways involving TGF-β. Epithelial homeostasis is thus maintained. As previously noted, they cite the loss of TGFBR3 expression as a key factor in the progression of breast cancer in its early stages.

    Work with the murine models demonstrated that the loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional dendritic cells (DC). “Alterations in these DC populations mediated Treg [regulatory T cell] infiltration and the suppression of antitumor immunity,” wrote the scientists.

    The researchers concluded that if TGF-β expression is inhibited, this would provide a novel method of tumor immunotherapy and that “sTGFBR3 levels could serve as a predictive immunotherapy biomarker.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »